Clinical Trials Directory

Trials / Completed

CompletedNCT01390597

Biomarkers in Tumor Tissue Samples From Patients With Peripheral T-cell Lymphoma or Natural Killer Cell Neoplasms

The Molecular Mechanisms of Transformation in Peripheral T-cell and NK Lymphomas

Status
Completed
Phase
Study type
Observational
Enrollment
32 (actual)
Sponsor
Eastern Cooperative Oncology Group · Network
Sex
All
Age
18 Years – 120 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat the cancer. PURPOSE: This research trial studies biomarkers in tumor tissue samples from patients with peripheral T-cell lymphoma or natural killer cell neoplasms.

Detailed description

OBJECTIVES: * To identify mutations in oncogenes and tumor suppressors of peripheral T-cell lymphoma or natural killer (NK) cell neoplasm. * To delineate the mechanisms that mediate oncogenic effects and their clinical prognostic significance in these diseases. * To perform a comprehensive mutation analysis via whole exome resequencing in a panel of peripheral T-cell or NK lymphomas. OUTLINE: Fixed paraffin-embedded tumor tissue samples are analyzed for mutations by the Illumina HiSeq platform. Sequencing reads are performed by GAPipeline version 1.5.1 and mapping on the human genome performed using the MAQ software version 0.7.1. Genes harboring validated somatic mutations are then amplified by PCR and analyzed by Sanger resequencing.

Conditions

Interventions

TypeNameDescription
GENETICDNA analysis
GENETICcytogenetic analysis
GENETICgene mapping
GENETICmutation analysis
GENETICpolymerase chain reaction
OTHERlaboratory biomarker analysis

Timeline

Start date
2011-06-28
Primary completion
2011-08-28
Completion
2011-08-28
First posted
2011-07-11
Last updated
2017-05-17

Source: ClinicalTrials.gov record NCT01390597. Inclusion in this directory is not an endorsement.